New Inhaler Devices - The Good, the Bad and the Ugly | Zendy

Federico Lavorini | Zendy; Giovanni Fontana | Zendy; Omar S. Usmani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New Inhaler Devices - The Good, the Bad and the Ugly

Author(s) -

Federico Lavorini,

Giovanni Fontana,

Omar S. Usmani

Publication year - 2014

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000363390

Subject(s) - medicine , dry powder inhaler , inhaler , copd , asthma , intensive care medicine , pulmonary disease , metered dose inhaler , drug delivery , drug , pharmacology , chemistry , organic chemistry

Drug delivery to the lungs is an effective way of targeting inhaled therapeutic aerosols and treating obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In the past 10 years, several new drugs for the management of asthma and COPD have been marketed and more are under development. These new therapeutic respiratory drugs have been furthered by innovations in all categories of pulmonary drug delivery systems to ensure optimal aerosolisation performance, consistency in efficacy and satisfactory patient adherence. In this review, we discuss the technological advances and innovations in recent inhaler devices and the evolving roles of pressurised metered-dose inhalers, dry powder inhalers and nebulisers, as well as their impact on patient adherence to treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research